open access
Novel hepatoselective insulin analog
open access
Abstract
RESEARCH DESIGN AND METHODS. Five normal human subjects received a subcutaneous bolus injection of either N B1 L-thyroxyl-insulin (B1-T4-Ins) or NPH insulin in random order. Insulin kinetics, relative effects on hepatic glucose production, and peripheral glucose uptake were studied using euglycemic clamp and stable isotope [D-6,6-2H2]glucose) dilution techniques. Blood samples were taken for the determination of total immunoreactive insulin/analog concentrations and for liquid chromatography to assess the protein binding of the analog in the circulation.
RESULTS. After subcutaneous administration, B1-T4-Ins was well tolerated and rapidly absorbed. The analog had a long serum half-life and was highly protein bound (~86%). Its duration of action, as judged by the duration of infusion of exogenous glucose to maintain euglycemia, was similar to that of NPH insulin. The effect of the analogs on hepatic glucose production was similar to that of NPH insulin, indicating equivalent hepatic potency. The analog demonstrated less effect on peripheral glucose uptake than NPH insulin (P = 0,025), had no effect on metabolic clearance rate of glucose, and exhibited a reduced capacity to inhibit lipolysis (P < 0,05).
CONCLUSIONS. When injected subcutaneously into normal human subjects, B1-T4-Ins is well tolerated, quickly absorbed, and highly protein bound, resulting in a long plasma half-life. This analog appears to have a hepatoselective action, and, therefore, has the potential to provide more physiological insulin action than the insulin preparations currently used.
Abstract
RESEARCH DESIGN AND METHODS. Five normal human subjects received a subcutaneous bolus injection of either N B1 L-thyroxyl-insulin (B1-T4-Ins) or NPH insulin in random order. Insulin kinetics, relative effects on hepatic glucose production, and peripheral glucose uptake were studied using euglycemic clamp and stable isotope [D-6,6-2H2]glucose) dilution techniques. Blood samples were taken for the determination of total immunoreactive insulin/analog concentrations and for liquid chromatography to assess the protein binding of the analog in the circulation.
RESULTS. After subcutaneous administration, B1-T4-Ins was well tolerated and rapidly absorbed. The analog had a long serum half-life and was highly protein bound (~86%). Its duration of action, as judged by the duration of infusion of exogenous glucose to maintain euglycemia, was similar to that of NPH insulin. The effect of the analogs on hepatic glucose production was similar to that of NPH insulin, indicating equivalent hepatic potency. The analog demonstrated less effect on peripheral glucose uptake than NPH insulin (P = 0,025), had no effect on metabolic clearance rate of glucose, and exhibited a reduced capacity to inhibit lipolysis (P < 0,05).
CONCLUSIONS. When injected subcutaneously into normal human subjects, B1-T4-Ins is well tolerated, quickly absorbed, and highly protein bound, resulting in a long plasma half-life. This analog appears to have a hepatoselective action, and, therefore, has the potential to provide more physiological insulin action than the insulin preparations currently used.
Keywords
B1-T4-Ins insulin; NPH insulin; type 1 diabetes
About this articleTitle
Novel hepatoselective insulin analog
Journal
Issue
Vol 2, No 2 (2001): Practical Diabetology
Article type
Other materials agreed with the Editors
Pages
151-158
Published online
2001-03-08
Page views
591
Article views/downloads
1916
DOI
10.5603/cd.8911
Bibliographic record
Diabetologia Praktyczna 2001;2(2):151-158.
Keywords
B1-T4-Ins insulin
NPH insulin
type 1 diabetes
Authors
Fariba Shojaee-Moradie
James K. Powrie
Erik Sundermann
Mark W. Spring
Achim Schüttler
Dietrich Brandenburg
Mark W. Spring
Achim Schüttler
Dietrich Brandenburg
Mark W. Spring
Achim Schüttler
Dietrich Brandenburg